Patent MX-PA02008893-A (MX)
Title: NOVEL 2,3,4,5 TETRAHYDRO 1H [1,4]DIAZEPINO[1,7a]INDOLE COMPOUNDS.
Inventor: ENNIS MICHAEL DALTON
IPC: A61P25/00
Filed: 2001-03-08
Abstract: A compound of formula (I) where a is a single bond or double bond, and where R1a, R1b, R2a and R2b are each independently (a) H, Cl, Br, I, F, CN, CF3, OCF3, OR5, CONR5R6, COR5, CO2R5, Y(CH2)mXR5 or YC(O)(CH2)mXR5, where m = 0 3, Y = CH2, S, O, or NR6, X = CH2, S, O, NR6; (b) (CH2)PAr where p = 0 3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO2, OR7, CF3, OCF3; SR7, SO2R7, SO2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; or (c) linear or branched C1 C8 alkyl, linear or branched C2 C8 alkenyl, linear or branched C2 C8 alkynyl, C3 C8 cycloalkenyl, or C3 C8 cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO2, COR7, OR7, NR7R8, SR7, CO2R7, CONR7R8 or NR7COR8; and where R3 is (a) H, Cl, Br, I, F, CN, CF3, OCF3, alkyl, Ar, OR5, SR5, CHO, CONR5R6, COR5, CO2R5, (Y)o(CH2)nXR5, C(O)C(O)NXR5R6, (Y)o(CH2)nC(O)XR5, C(O)(CH2)nXR5, (Y)o(CH2)nN(R6)C(O)NR5R6, where o = 0 or 1, n = 0 3, X = CH2, S, O, or NR6 and Y=CH2, S, O or NR6, where Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO2, OR7, CF3, OCF3, SR7, SO2R7, SO2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; (b) linear or branched C1 C8 alkyl, linear or branched C2 C8 alkenyl, linear or branched C2 C8 alkynyl, C3 C8 cycloalkyl, C3 C8 cycloalkenyl, or C3 C8 cycloalkynyl; wherein any of these groups may be optionally substituted with one or more of the following: halogen, CN, NO2, COR10, OR10, NR10R8, SR10, CO2R10, CONR10R8 or NR10COR8; and where R4, R5 and R6 are each independently (a) H, linear or branched C1 C8 alkyl, linear or branched C2 C8 alkenyl, linear or branched C2 C8 alkynyl, C3 C8 cycloalkyl, C3 C8 cycloalkenyl, or C3 C8 cycloalkynyl; wherein any of these groups other than H may be optionally substituted with one or more of the following: halogen, CN, NO2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11 or NR10COR11; or where R5 and R6 are linked to form a 3 to 8 member ring; or (b) (CH2)pAr where p = 0 3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO2, OR7, CF3, OCF3, SR7, SO2R7, SO2NR7R8, NR7R8, CONR7R8, NR7COR8, NR7CONR8R9, CO2R7, COR7, or R7; and where R7, R8, and R9 are each independently (a) H, linear or branched C1 C8 alkyl, linear or branched C2 C8 alkenyl, linear or branched C2 C8 alkynyl, C3 C8 cycloalkyl, C3 C8 cycloalkenyl, or C3 C8 cycloalkynyl groups, wherein any of these groups other than H may be optionally substituted with halogen, CN, NO2, COR10, OR10, NR10R11, SR10, CO2R10, CONR10R11, NR10COR11, NR10CONR11R12, or where R7, R8, or R9 are linked to form a ring; (b) (CH2)pAr where p = 0 3 and Ar is aryl or heteroaryl optionally substituted with one or more of the following: H, halogen, CN, NO2, OR10, CF3, OCF3, SR10, SO2R10, SO2NR10R11, NR10R11, CONR10R11, NR10COR11, NR10CONR11R12, CO2R10, COR10, or R10; and where R10, R11 and R12 are each n any independently H, linear or branched C1 C8 alkyl, linear or branched C2 C8 alkenyl, linear or branched C2 C8 alkynyl, C3 C8 cycloalky, C3 C8 cycloalkenyl, or C3 C8 cycloalkynyl; or a stereoisomer or pharmaceutically acceptable salt thereof.